Bibliografía Comentada

Javier de Castro Carpeño

Responsable de la sección
Hospital Universitario La Paz. Madrid

Esta sección está supervisada por el grupo de expertos de Oncobyg. La información recogida en esta web refleja únicamente la opinión del grupo de expertos de Oncobyg, y sus recomendaciones no pretenden sustituir a las directrices de consensos de sociedades médicas o de las guías de tratamiento oncológico vigentes en la actualidad

Cáncer de pulmón

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. J Clin Oncol. 2016 Jun 27. pii: JCO667162. [Epub ahead of print]

5 de octubre de 2016


Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, et al. Oncologist. 2016;21(6):684-91.

5 de octubre de 2016


Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.

Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Virchows Arch. 2016;468(5):511-25

5 de octubre de 2016


The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis.Immunotherapy.

Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Mountzios G, de Mello RA. 2016;8(4):479-88.

5 de octubre de 2016


Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O’Connell J, et al. Ann Oncol (2015) 26(7):1421–7.

5 de octubre de 2016


MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Reungwetwattana T, Ou SH. Transl Lung Cancer Res. 2015;4(6):820-4

5 de octubre de 2016


Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Lancet Oncol. 2016;17(7):984-93.

5 de octubre de 2016


PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, et al. Proc Natl Acad Sci U S A (2015) 112(11):3493–8.

5 de octubre de 2016


Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study.

Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al. J Clin Oncol (2016) 34(7):661–8.

5 de octubre de 2016


The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies.

Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. Clin Cancer Res (2015) 21(17):3924–33.

5 de octubre de 2016


Inhibidores EGFR de tercera generación

Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. N Engl J Med (2015) 372(18):1689–99.

5 de octubre de 2016


Recent Advances in Targetable Therapeutics in Metastatic non-Squamous nSCLC.

Bansal P, Osman D, Gan GN, Simon GR and Boumber Y. N Engl J Med (2015) 372(18):1689–99.

5 de octubre de 2016


Liquid biopsies: genotyping circulating tumor DNA.

Diaz LA, Jr., Bardelli A. J Clin Oncol. 2014;32:579-86.

1 de octubre de 2014


Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.

Travis WD, Brambilla E, Noguchi M, et al. Arch Pathol Lab Med. 2013 ;137:668-84.

1 de octubre de 2014


New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.

Travis WD, Brambilla E, Riely GJ. J Clin Oncol. 2013;31:992-1001.

1 de octubre de 2014


KRAS mutation: should we test for it, and does it matter?

Roberts PJ, Stinchcombe TE. J Clin Oncol. 2013;31:1112-21.

1 de octubre de 2014


New targetable oncogenes in non-small-cell lung cancer.

Oxnard GR, Binder A, Janne PA. J Clin Oncol. 2013;31:1097-104.

1 de octubre de 2014


Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Kwak EL, Bang yJ, Camidge DR, et al. N Engl J Med 2010; 363: 1693-703.

1 de octubre de 2014


Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, et al. Lancet Oncol. 2012;13:239-46.

1 de octubre de 2014


Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Lindeman NI, Cagle PT, Beasley MB, et al. J Thorac Oncol 2013; 8: 823-859.

1 de octubre de 2014